Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

This review examines the clinical presentation of alopecia areata in children and compares it to adult-onset cases, noting that data on pediatric cases is scarce and often varies, with reported onset typically between ages 6 and 12.

This retrospective study at the University Clinical Centre in Gdańsk reported that 77.9% of patients with alopecia areata were treated with off-label pharmacotherapy, predominantly glucocorticosteroids, highlighting a reliance on these therapies in European clinical practice.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.

This study assessed the psychosocial impact and disease burden of alopecia areata among adolescents and adults in Australia, finding substantial impacts on physical, emotional, and quality of life overall, with greater disease burden in patients experiencing more extensive hair loss.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

In this study, health state utility values revealed a significant impact on quality of life for patients with alopecia areata, particularly those with more extensive hair loss.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

This study found that although both adults and adolescents with alopecia areata experience a significant quality of life impact from ≥50% scalp hair loss, the impact is greater for adolescents, as indicated by their higher Dermatology Life Quality Index scores.

This study indicates that the EQ-5D-5L may not effectively capture the burden of alopecia areata on patients' health-related quality of life, and suggests that alternative measures might better assess treatment benefits related to hair regrowth.

This paper reviews current and developing treatments for severe alopecia areata but reports no new clinical findings; the authors highlight the need for standardized treatment protocols.

This study describes a new treatment algorithm for alopecia areata that includes both disease severity and quality-of-life considerations, highlighting recent therapeutic advances and the need for future validation and access equity.

This study on alopecia areata meta-analyses highlights the risk of misleading results when ineffective, unsafe, or unapproved dosing regimens are included, recommending methodological safeguards to ensure accurate data interpretation and avoid inappropriate causal inferences.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.

This review summarizes current knowledge on the role of the JAK/STAT signaling pathway in alopecia areata and suggests moderate efficacy of systemic inhibitors, with low adverse events but high recurrence rates.

This review discusses the role of Janus-kinase inhibitors in treating severe atopic dermatitis and alopecia areata, presenting case studies that show their efficacy and calling for further research on long-term effectiveness and safety.

In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

The document suggests a bacteria plays a significant role in acne rosacea and that white hair can regain color after transplant, meriting more research on reversing grey hair.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study found that Baricitinib effectively reduced alopecia severity in adults with severe alopecia areata during a 12-month observation period, especially when initiated in patients with milder baseline conditions and elevated ESR; no serious adverse events were reported.

In this study, researchers reported that specific gene polymorphisms in Jiangnan cashmere goats, particularly SNPs in the HOXC13 and WNT4 genes, were significantly associated with key economic traits like birth weight and yearling weight, providing molecular markers for breeding and enhancing economic trait stability.

This article reviews 27 small-molecule drugs approved by the FDA in 2024, noting that among them, eight "first-in-class" drugs with breakthrough therapy status show distinct mechanisms and substantial efficacy improvements in various conditions like cancer and chronic diseases.

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.

JAK inhibitors are generally safe for treating alopecia areata.

This study evaluated the use of JAK inhibitors in patients with alopecia areata episodes lasting at least eight years and found that while the overall therapeutic response was limited, a subset of patients achieved meaningful hair regrowth, suggesting these treatments as a viable option.